KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Net Cash Flow: 2009-2024

Historic Net Cash Flow for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Dec 2024 value amounting to $908.2 million.

  • Jazz Pharmaceuticals' Net Cash Flow fell 84.17% to $136.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$896.3 million, marking a year-over-year decrease of 201.85%. This contributed to the annual value of $908.2 million for FY2024, which is 45.62% up from last year.
  • Latest data reveals that Jazz Pharmaceuticals reported Net Cash Flow of $908.2 million as of FY2024, which was up 45.62% from $623.7 million recorded in FY2023.
  • In the past 5 years, Jazz Pharmaceuticals' Net Cash Flow registered a high of $908.2 million during FY2024, and its lowest value of -$463.1 million during FY2021.
  • Moreover, its 3-year median value for Net Cash Flow was $623.7 million (2023), whereas its average is $609.4 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first slumped by 210.25% in 2021, then skyrocketed by 163.97% in 2022.
  • Jazz Pharmaceuticals' Net Cash Flow (Yearly) stood at $420.1 million in 2020, then tumbled by 210.25% to -$463.1 million in 2021, then skyrocketed by 163.97% to $296.3 million in 2022, then spiked by 110.52% to $623.7 million in 2023, then soared by 45.62% to $908.2 million in 2024.